Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition
Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition…
Lucid Diligence Brief: Basata $21 million Series A
Lucid Diligence Brief: Basata $21 million Series A Professional audiences only.…
Lucid Diligence Brief: Lucent Diagnostics and Tempus AI Partnership
Lucid Diligence Brief: Lucent Diagnostics and Tempus AI Partnership…
Lucid Diligence Brief: Blackstone Life Sciences $250 million investment in Anagram Therapeutics
Lucid Diligence Brief: Blackstone Life Sciences $250 million investment in…
Lucid Diligence Brief: Roche to acquire PathAI
Lucid Diligence Brief: Roche acquires PathAI for USD 1.05B to advance AI…
Lucid Diligence Brief: SiranBio and GSK SA030 Licensing Agreement
Lucid Diligence Brief: SiranBio and GSK SA030 Licensing Agreement Professional…
Lucid Diligence Brief: Bayer to Acquire Perfuse Therapeutics for Up to $2.45B
Lucid Diligence Brief: Bayer to Acquire Perfuse Therapeutics for Up to $2.45B…
Lucid Diligence Brief: Apertura Gene Therapy and TSC Alliance Collaboration
Lucid Diligence Brief: Apertura Gene Therapy and TSC Alliance Collaboration…
Lucid Diligence Brief: Arrowhead ARO-PNPLA3 licensed to Madrigal
Lucid Diligence Brief: Arrowhead ARO-PNPLA3 licensed to Madrigal Professional…
Lucid Diligence Brief: Latus Bio $97 million Series A
Lucid Diligence Brief: Latus Bio $97 million Series A Professional audiences…
Lucid Diligence Brief: UCB acquisition of Candid Therapeutics
Lucid Diligence Brief: UCB acquisition of Candid Therapeutics Professional…
Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Axoft $55 million Series A Professional audiences only.…